(R)-Fangchinoline
(Synonyms: 汉防己乙素,Thalrugosine; Thaligine) 目录号 : GC64179Fangchinoline, a bisbenzylisoquinoline alkaloid, is a novel HIV-1 inhibitor with pain-relieving, blood pressure-depressing, and antibiotic activities.
Cas No.:33889-68-8
Sample solution is provided at 25 µL, 10mM.
Fangchinoline, a bisbenzylisoquinoline alkaloid, is a novel HIV-1 inhibitor with pain-relieving, blood pressure-depressing, and antibiotic activities.
Fangchinoline (FCL) exhibits antiviral activity against HIV-1 laboratory strains NL4-3, LAI and BaL in MT-4 and PM1 cells with a 50% effective concentration ranging from 0.8 to 1.7 ?M. The compound targets a late event in infection cycle. Fangchinoline inhibits HIV-1 replication by interfering with gp160 proteolytic processing[1]. FCL inhibits autophagosomes-lysosomes fusion, decreases the activities of cathepsin B and cathepsin D and affects the cellular acidification. FCL also increases the nuclear translocation of transcription factor EB (TFEB), a master regulator of autophagic and lysosomal genes, and the mRNA expressions of TFEB-targeted genes, such as SQSTM1, MAP1LC3B, and UVRAG. Knockdown of TFEB by using small inference RNA decreases the FCL-induced expression of LC3-II and the formation of GFP-LC3 puncta[2]. Fangchinoline effectively suppresses proliferation and invasion of SGC7901 cell lines, but not MKN45 cell lines by inhibiting the expression of PI3K and its downstream pathway. fangchinoline targets PI3K in tumor cells that express PI3K abundantly and inhibits the growth and invasive ability of the tumor cells[3]. Fangchinoline is also a non-specific calcium antagonist[4].
Fangchinoline attenuates morphine (SC)-induced antinociception in a dose-dependent manner with significant effect at doses of 30 and 60mg/kg body wt. (IP) in the tail-flick test but not the tail-pinch tests, carried out in mice[4].
[1] Wan Z, et al. PLoS One. 2012, 7(6):e39225. [2] Zheng-Hai Tang, et al. RSC Adv. 2017,7:42597-42605. [3] Tian F, et al. Int J Oncol. 2015, 46(6):2355-63.
Cas No. | 33889-68-8 | SDF | Download SDF |
别名 | 汉防己乙素,Thalrugosine; Thaligine | ||
分子式 | C37H40N2O6 | 分子量 | 608.72 |
溶解度 | DMSO : 50 mg/mL (82.14 mM; Need ultrasonic) | 储存条件 | 4°C, protect from light |
General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。 储备液的保存方式和期限:-80°C 储存时,请在 6 个月内使用,-20°C 储存时,请在 1 个月内使用。 为了提高溶解度,请将管子加热至37℃,然后在超声波浴中震荡一段时间。 |
||
Shipping Condition | 评估样品解决方案:配备蓝冰进行发货。所有其他可用尺寸:配备RT,或根据请求配备蓝冰。 |
制备储备液 | |||
1 mg | 5 mg | 10 mg | |
1 mM | 1.6428 mL | 8.214 mL | 16.4279 mL |
5 mM | 0.3286 mL | 1.6428 mL | 3.2856 mL |
10 mM | 0.1643 mL | 0.8214 mL | 1.6428 mL |
第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量) | ||||||||||
给药剂量 | mg/kg | 动物平均体重 | g | 每只动物给药体积 | ul | 动物数量 | 只 | |||
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系GLPBIO为您提供正确的澄清溶液配方) | ||||||||||
% DMSO % % Tween 80 % saline | ||||||||||
计算重置 |
计算结果:
工作液浓度: mg/ml;
DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,
体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL saline,混匀澄清。
1. 首先保证母液是澄清的;
2.
一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。
Quality Control & SDS
- View current batch:
- Purity: >99.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet